Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Bipolar Disorder

In brief

The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.

Key facts

Study ID

NCT00854737

Run by

Mclean Hospital

People needed

90

Starts

2004-07-01

Expected to finish

2010-07-01

Last updated by the study team

2012-04-20

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• bipolar disorder
• mood episode within past year
• stable medication regimen

You may not qualify if…

• primary psychiatric disorder other than bipolar disorder
• significant suicide or homicide risk
• unstable medical conditions
• current or planned pregnancy
• lactose intolerance
• medications affecting lipid absorption or metabolism
• clozapine treatment

Where it is running

• McLean Hospital — Belmont, Massachusetts, United States
• Jersey Shore University Medical Center — Neptune City, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.